20.500.12556/DiRROS-21754 Prospective observational study of COVID-19 vaccination in patients with thoracic malignancies adverse events, breakthrough infections and survival outcomes Abstract: Due to the devastating COVID-19 pandemic, a preventive tool in the form of vaccination was introduced. Thoracic cancer patients had one of the highest rates of morbidity and mortality due to COVID-19 disease, but the lack of data about the safety and effectiveness of vaccines in this population triggered studies like ours to explore these parameters in a cancer population. Out of 98 patients with thoracic malignancies vaccinated per protocol, 60–75% experienced some adverse events (AE) after their first or second vaccination, most of them were mild and did not interfere with their daily activities. Out of 17 severe AEs reported, all but one were resolved shortly after vaccination. No significant differences were noted considering AE occurrence between different cancer therapies received after the first or second vaccination dose, p = 0.767 and p = 0.441, respectively. There were 37 breakthrough infections either after the first (1), second (13) or third (23) vaccine dose. One patient died as a direct consequence of COVID-19 infection and respiratory failure, and another after disease progression with simultaneous severe infection. Eight patients had moderate disease courses, received antiviral therapies and survived without consequences. Vaccination did not affect the time to disease progression or death from underlying cancer. thoracic malignancies cancer therapy COVID-19 vaccination adverse events breakthrough infection rak pljuč onkološko zdravljenje cepljenje proti COVID-19 neželeni dogodki prebojna okužba true false true MDPI AG, 2013- Biomedicines Angleški jezik Slovenski jezik © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Neznano 2025-03-24 10:51:50 2025-03-24 10:51:50 2025-10-24 03:49:45 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis vira z dne 15. 3. 2024; str. 535-1-535-12 Vol. 12 2024 0000-00-00 Zaloznikova NiDoloceno apc 2024-02-15 2024-02-26 2024-02-27 616-006 2227-9059 10.3390/biomedicines12030535 189077251 https://www.mdpi.com/2227-9059/12/3/535 1 9d46c058-0895-11f0-963a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=31326 RAZ_Janzic_Urska_2024.pdf RAZ_Janzic_Urska_2024.pdf 1 94910CE6B577307EF810D4966A0FBB14 424b805ae2bab8798949c0bb83afb22c86b3784d51468f8872f88ca019f9874f 2ac30d0b-0896-11f0-963a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=31327 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0